Compare LULU & NBIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LULU | NBIX |
|---|---|---|
| Founded | 1998 | 1992 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Apparel | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.5B | 13.2B |
| IPO Year | 2007 | 1996 |
| Metric | LULU | NBIX |
|---|---|---|
| Price | $132.66 | $148.83 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 25 | 22 |
| Target Price | ★ $190.26 | $180.91 |
| AVG Volume (30 Days) | ★ 2.8M | 1.1M |
| Earning Date | 06-04-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 41.95 |
| EPS | ★ 13.26 | 1.91 |
| Revenue | ★ $11,102,600,000.00 | $161,626,000.00 |
| Revenue This Year | $5.52 | $24.73 |
| Revenue Next Year | $4.68 | $13.14 |
| P/E Ratio | ★ $9.98 | $77.03 |
| Revenue Growth | 4.86 | ★ 977.51 |
| 52 Week Low | $127.80 | $115.66 |
| 52 Week High | $340.25 | $160.18 |
| Indicator | LULU | NBIX |
|---|---|---|
| Relative Strength Index (RSI) | 31.58 | 75.91 |
| Support Level | N/A | $133.96 |
| Resistance Level | $170.94 | $148.99 |
| Average True Range (ATR) | 4.78 | 3.58 |
| MACD | -1.79 | 1.95 |
| Stochastic Oscillator | 11.23 | 97.46 |
Lululemon Athletica designs, distributes, and markets athletic apparel, footwear, and accessories for women, men, and girls. The company offers pants, shorts, tops, and jackets for both leisure and athletic activities such as yoga and running. Lululemon also sells fitness accessories, such as bags, yoga mats, and equipment. It sells its products through digital channels, a small number of wholesale partners, more than 800 company-owned stores in about two dozen countries in North America, Asia, and Western Europe, and about 45 franchised locations in the Middle East and Europe. The company was founded in 1998 and is based in Vancouver, Canada.
Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.